-
公开(公告)号：US20060014241A1
公开(公告)日：2006-01-19
申请号：US10499111
申请日：2003-01-03
申请人： Wolfgang Glaesner , Wayne Kohn , Rohn Millican , Lianshan Zhang
发明人： Wolfgang Glaesner , Wayne Kohn , Rohn Millican , Lianshan Zhang
IPC分类号： A61K38/26 , C07H21/04 , C12P21/06 , C07K14/605
CPC分类号： C07K14/605 , A61K38/00 , C07K2319/00
摘要： The invention encompasses GLP-1 peptides with modifications at various positions coupled with an extended C-terminus that provides increased stability.
-
公开(公告)号：US20060252693A1
公开(公告)日：2006-11-09
申请号：US11481552
申请日：2006-07-06
申请人： Wolfgang Glaesner , Rohn Millican , Lianshan Zhang
发明人： Wolfgang Glaesner , Rohn Millican , Lianshan Zhang
IPC分类号： A61K38/26
CPC分类号： C07K14/605 , A61K38/00
摘要： Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 7, 8, 12, 16, 18, 19, 20, 22, 25, 27, 30, 33, and 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed.
摘要翻译： 公开了具有以下一个或多个位置的修饰的胰高血糖素样肽-1（GLP-1）化合物：7,8,12,16,18,19,20,22,25,27,30,33和 还公开了使用这些GLP-1化合物治疗需要GLP-1受体刺激的受试者的方法。
-
公开(公告)号：US20070265200A1
公开(公告)日：2007-11-15
申请号：US10592016
申请日：2005-03-04
摘要： The invention provides FGF-21 compounds covalently attached to at least one polyethylene glycol molecule or derivative thereof, resulting in a biologically active polypeptide with an extended elimination half-life and a slower clearance when compared to that of non-PEGylated polypeptide. These PEGylated FGF-21 compounds and compositions are useful in treating diabetes, obesity, and metabolic syndrome.
摘要翻译： 本发明提供与至少一种聚乙二醇分子或其衍生物共价连接的FGF-21化合物，当与非聚乙二醇化多肽相比时，产生具有延长的消除半衰期和较慢清除率的生物活性多肽。 这些聚乙二醇化FGF-21化合物和组合物可用于治疗糖尿病，肥胖症和代谢综合征。
-
公开(公告)号：US20070237768A1
公开(公告)日：2007-10-11
申请号：US11578614
申请日：2005-05-02
申请人： Wolfgang Glaesner , Rohn Millican , Yu Tian , Sheng-Hung Tschang
发明人： Wolfgang Glaesner , Rohn Millican , Yu Tian , Sheng-Hung Tschang
CPC分类号： C07K14/50 , A61K38/00 , C07K2319/30 , C07K2319/31 , C07K2319/75
摘要： The invention provides specific FGF-21 compounds fused to specific IgG4-Fc or HSA derivatives resulting in fusion proteins that are biologically active with an extended elimination half-life and a slower clearance. These FGF-21 compound fusion proteins and compositions are useful in treating type 2 diabetes, obesity, and metabolic syndrome.
摘要翻译： 本发明提供与特异性IgG4-Fc或HSA衍生物融合的特异性FGF-21化合物，其导致具有生物学活性且融合蛋白质，其具有延长的消除半衰期和较慢的间隙。 这些FGF-21复合融合蛋白和组合物可用于治疗2型糖尿病，肥胖症和代谢综合征。
-
公开(公告)号：US20070100133A1
公开(公告)日：2007-05-03
申请号：US11521059
申请日：2006-09-14
IPC分类号： C07K14/51
CPC分类号： C07K14/505 , A01K2217/05 , A61K38/1816 , A61K47/60
摘要： The present invention addresses the need for better pharmaceutical agents for teating anemias by providing polymer derivatized non-glycosylated erythropoietic compounds which show stability and bioactivity in vivo. The invention further provides methods for preparing these derivatived proteins which involves the use of a linkerless aldehyde modification process.
摘要翻译： 本发明通过提供在体内显示稳定性和生物活性的聚合物衍生的非糖基化的红细胞生成化合物来满足对更好的药剂的需求。 本发明还提供了制备这些衍生蛋白质的方法，其涉及使用无接头的醛修饰方法。
-
公开(公告)号：US20070036806A1
公开(公告)日：2007-02-15
申请号：US10558627
申请日：2004-06-10
申请人： Wolfgang Glaesner , Rohn Millican , Andrew Vick
发明人： Wolfgang Glaesner , Rohn Millican , Andrew Vick
IPC分类号： A61K39/395 , C07K16/46 , C07K14/605
CPC分类号： C07K16/26 , A61K38/00 , C07K14/503 , C07K14/605 , C07K2319/30
摘要： The invention provides specific GLP-1 analogs fused to specific IgG4-Fc derivatives. These fusion proteins have an increased half-life, decreased immunogenicity, and reduce effector activity. The fusion proteins are useful in treating diabetes, obesity, irritable bowel syndrome and other conditions that would be benefited by lowering plasma glucose, inhibiting gastric and/or intestinal motility and inhibiting gastric and/or intestinal emptying, or inhibiting food intake.
摘要翻译： 本发明提供了与特异性IgG4-Fc衍生物融合的特异性GLP-1类似物。 这些融合蛋白具有增加的半衰期，免疫原性降低，并降低效应子活性。 融合蛋白可用于治疗糖尿病，肥胖症，肠易激综合征和其它通过降低血浆葡萄糖，抑制胃和/或肠运动并抑制胃和/或肠排空或抑制食物摄取而受益的病症。
-
公开(公告)号：US20060263849A1
公开(公告)日：2006-11-23
申请号：US11436457
申请日：2006-05-18
申请人： Wolfgang Glaesner , Rohn Millican
发明人： Wolfgang Glaesner , Rohn Millican
IPC分类号： C12P21/06 , C07H21/04 , C07K14/605
CPC分类号： A61K38/26 , C07K14/47 , C07K14/605
摘要： Disclosed are glucagon-like peptide-1 (GLP-1) compounds with modifications at one or more of the following positions: 11, 12, 16, 22, 23, 24, 25, 27, 30, 33, 34, 35, 36, or 37. Methods of treating a subject in need of GLP-1 receptor stimulation using these GLP-1 compounds are also disclosed.
摘要翻译： 公开了在以下一个或多个位置具有修饰的胰高血糖素样肽-1（GLP-1）化合物：11,12,16,22,23,24,25,27,30,33,34,35,36 或37.还公开了使用这些GLP-1化合物治疗需要GLP-1受体刺激的受试者的方法。
-
-
-
-
-
-
搜索结果
7 条记录 (耗时 0.038 秒)
